COMPANY

Almatica Pharma

Almatica, a subsidiary of Alvogen, is a specialty pharmaceuticals company that is focused on developing medicines. Our portfolio is concentrated within the therapeutic areas of psychiatry and neurology. From company website Source · Oct 12, 2026

Keywords: neurology

Profile checked Oct 10, 2026

2FDA records (2 yrs)

Timeline

Feb 27, 2026 FDA FDA Original approval: DULOXETINE HYDROCHLORIDE (duloxetine hydrochloride) — NDA219131, Feb 27, 2026. Applicant at approval: Almatica Pharma, LLC. source ↗
Aug 29, 2025 FDA FDA Original approval: ESCITALOPRAM (escitalopram oxalate) — NDA219130, Aug 29, 2025. Applicant at approval: Almatica Pharma, LLC. source ↗

FDA records (last 2 years)

Feb 27, 2026 FDA Original approval: DULOXETINE HYDROCHLORIDE (duloxetine hydrochloride) — NDA219131, Feb 27, 2026. Applicant at approval: Almatica Pharma, LLC. source ↗
Aug 29, 2025 FDA Original approval: ESCITALOPRAM (escitalopram oxalate) — NDA219130, Aug 29, 2025. Applicant at approval: Almatica Pharma, LLC. source ↗

Connect

See your connections at Almatica Pharma on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12